LXEO – lexeo therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.
Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy [Yahoo! Finance]
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
Form 8-K Lexeo Therapeutics, Inc. For: Jan 12
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC
Form EFFECT Lexeo Therapeutics, Inc.
Form 424B3 Lexeo Therapeutics, Inc.
Form 4 Lexeo Therapeutics, Inc. For: Nov 18 Filed by: Townsend Richard Nolan
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.